每经记者｜程雅 每经编辑｜文多 艾迪，是曾在资本市场名噪一时的创投家，二十世纪60年代末出生的她，具有近20年的企业管理和投融资经验。 如今，她掌舵（实控）的两家上市公司，却在资本市场的深水区挣扎。 其中一家是*ST工智（以下为行文统一称为哈工智能，SZ000584，股价1.46元，市值11.11亿元），公司已在6月12日收到了终止上市的决定，股票自6月20日 起正式进入退市整理期。 另一家是*ST天喻（即天喻信息，SZ300205，股价3.97元，市值17.07亿元），该公司同样已敲响"*ST"的警钟，且持续经营能力存疑。 6月13日，《每日经济新闻》记者致电哈工智能，工作人员表示，公司已经决定不申请复核了，后续的退市程序将按照相应的流程进行。 图片来源：网络截图 图片来源：公告截图 故事的主角此时终于登场。2015年，艾迪旗下的联创投资集团股份有限公司（以下简称"联创投资"）在新三板挂牌（NQ833502），这家公司成立于2011 年，当时已在资本市场崭露头角。 2017年初，股东双良科技以高达32.4亿元的价格，将持有的友利控股29.9%的股权全部转让给无锡哲方哈工智能机器人投资企业（有限合伙）（乔徽实 ...

Core Viewpoint - The company, Hangzhou Dihun Network Technology Co., Ltd., reported a significant decline in revenue and net profit for the year 2024, primarily driven by the performance of its flagship game "Dream Three Kingdoms" which has been operational for over 15 years [1][3][5]. Financial Performance - In 2024, the company achieved operating revenue of 550 million yuan, a year-on-year decrease of 18.71% - The net profit attributable to the parent company was 30.58 million yuan and 5.30 million yuan, reflecting declines of 46.2% and 91.1% respectively [1][3]. Game Performance Metrics - Revenue from "Dream Three Kingdoms" accounted for 65.27% of total revenue - The game experienced a decline in key performance indicators over the past three years: - Revenue in 2024 was 359.26 million yuan, down 18.46% from 2023 - Total transaction amount decreased by 38.47% to 308.06 million yuan in 2024 - Monthly active users fell to 566,400, a decrease of 3.90% [2][3][8]. Revenue Recognition and Accounting Practices - The company recognizes revenue based on the consumption of virtual items and the lifecycle of paying players, which aligns with the accounting standards [4][5]. - The average revenue per user (ARPU) in 2024 was 45.32 yuan, down 35.98% from the previous year [2][3]. Business Model and Cost Structure - The company operates under four business models: self-operated, authorized, joint operation, and agency operation - Despite a decline in revenue, operating costs increased by 12.35% due to rising costs associated with mobile game licensing and operational expenses [5][8]. Cost Composition - The main components of operating costs in 2024 included: - Employee compensation: 78.91 million yuan, up 12.31% - Revenue sharing and licensing fees: 32.15 million yuan, up 48.46% - Server rental fees: 16.81 million yuan, down 10.63% [8][9]. Future Game Development and Risks - The company has several new game products in the pipeline, with various stages of licensing and release planned for 2025 - However, there are risks associated with the timely launch and performance of these new titles, influenced by market conditions and development timelines [4][5][6].

Core Viewpoint - The financial performance of Buchang Pharma has significantly deteriorated in 2024, with a revenue drop of 17% and a net loss of 5.5 billion yuan, marking a 274% decline in net profit compared to the previous year [2][3][4]. Financial Performance Summary - In 2024, the company's operating revenue was 11 billion yuan, down from 13.25 billion yuan in 2023, reflecting a decrease of 16.91% [3]. - The net profit attributable to shareholders was a loss of 553.8 million yuan, compared to a profit of 319 million yuan in 2023, indicating a decline of 273.62% [3][4]. - The company reported a significant impairment of goodwill amounting to 853 million yuan, primarily related to its subsidiaries Tonghua Guhong and Jilin Tiancai [5][20]. Business Operations and Challenges - The decline in revenue and profit is attributed to the removal of several products from the medical insurance catalog and increased scrutiny on certain products, leading to reduced sales [4][13]. - The company's total revenue has decreased from 160 billion yuan in 2020 to 110 billion yuan in 2024, a drop of over 30% [16]. - Sales of key products have plummeted, with some experiencing a sales decline of 50% to 85% from 2022 to 2023 [18]. Acquisition and Goodwill Issues - Buchang Pharma's acquisitions of Jilin Tiancai and Tonghua Guhong from 2012 to 2015 resulted in a total goodwill of approximately 49.97 billion yuan, which constituted 33% of the company's total assets at that time [8][9]. - The company has faced continuous goodwill impairment, totaling 45.3 billion yuan from 2021 to 2024, which is 88% of the initial goodwill [24]. Sales and Marketing Expenses - The company's sales expense ratio has consistently exceeded the industry average, with a sales expense rate of 39% in 2024, 11 percentage points higher than the industry average [27][28]. - A significant portion of sales expenses (93%) is allocated to market and academic promotion fees, raising concerns about the efficiency of spending [29][30]. Research and Development (R&D) Expenditure - Despite claims of transitioning to a product-driven and technology-oriented company, R&D expenditure has remained low, with a rate of only 2-3% over the past five years [35]. - The company has increasingly capitalized R&D expenses, with the capitalized portion rising from 26% in 2020 to 52% in 2024, suggesting potential manipulation of profit figures [37][38].

Core Viewpoint - The financial performance of Buchang Pharma has significantly deteriorated in 2024, with a revenue drop of 17% and a net loss of 5.5 billion yuan, marking a 274% decline in net profit compared to the previous year [2][3][4]. Financial Performance Summary - In 2024, the company's operating revenue was 11 billion yuan, down from 13.25 billion yuan in 2023, reflecting a decrease of 16.91% [3]. - The net profit attributable to shareholders was a loss of 553.8 million yuan, compared to a profit of 319 million yuan in 2023, indicating a decline of 273.62% [3][4]. - The company also reported a significant impairment of goodwill amounting to 853 million yuan, primarily related to its subsidiaries [5][20]. Business Operations and Challenges - The decline in revenue and profit is attributed to the removal of several products from the medical insurance catalog and increased scrutiny on certain products, leading to reduced sales [4][13]. - The company has faced continuous challenges since 2020, with total revenue decreasing from 160 billion yuan in 2020 to 110 billion yuan in 2024, a drop of over 30% [16]. Goodwill Impairment and Acquisitions - Buchang Pharma's acquisitions of Jilin Tiancai and Tonghua Guhong from 2012 to 2015 resulted in a total goodwill of approximately 50 billion yuan, which constituted 33% of the company's total assets at that time [8][9]. - The company has been forced to recognize substantial goodwill impairments, totaling 45.3 billion yuan from 2021 to 2024, which is 88% of the initial goodwill [24]. Sales and Marketing Expenses - The company's sales expense ratio has consistently exceeded the industry average, with a sales expense rate of 39% in 2024, significantly higher than the industry average of 28% [27][28]. - A large portion of the sales expenses (93%) is allocated to market and academic promotion fees, raising concerns about the efficiency of spending [29][30]. Research and Development - Despite claims of transitioning to a product-driven and technology-driven company, Buchang Pharma's R&D expenditure has remained low, with a research expense rate of only 2-3% over the past five years [35]. - The company has increasingly capitalized its R&D expenses, with the capitalized portion rising from 26% in 2020 to 52% in 2024, which may obscure the true profitability [37][38].

Core Viewpoint - Nasda's frequent external mergers and acquisitions appear to lack growth quality despite significant scale, with nearly 200 billion in revenue over ten years but a loss of 1 billion. The aftereffects of acquisitions are becoming evident, as the company plans to sell Lexmark International, acquired for over 10 billion, for less than 150 million, raising questions about the underlying motives and the quality of the acquired assets [1][4][13]. Group 1: Financial Performance - The company has reported cumulative revenue of nearly 200 billion over ten years but has incurred a total loss of 1 billion [7][9]. - Lexmark International, acquired for 27 billion USD, has contributed significant revenue but limited profit, with an average annual revenue contribution of around 15 billion from 2017 to 2024, yet the operating profit margin has been below 3% [9][12]. - The company’s revenue has significantly declined since 2019, with a notable drop in performance leading to substantial goodwill impairment in 2023 [15][19]. Group 2: Acquisition Strategy - From 2015 to 2021, Nasda engaged in acquisitions totaling over 25 billion, including the significant purchase of Lexmark International [5][6]. - The company plans to sell Lexmark International for a price significantly lower than its acquisition cost, raising concerns about the rationale behind such a decision [13][23]. - The acquisition of BenTu Electronics was marked by high premiums, with the transaction valued at 6.6 billion, involving related parties, which raises questions about potential capital arbitrage [24][25]. Group 3: Goodwill and Asset Quality - As of 2024, the company reported a goodwill balance of 135 billion, primarily from the Lexmark acquisition, which has not been adequately impaired despite declining revenues [15][20]. - The company has faced scrutiny regarding the reasonableness of its goodwill impairment assessments, particularly in light of significant revenue declines and unfulfilled performance commitments from acquired entities [16][19]. - Lexmark's own financials indicate a concerning trend, with its goodwill consistently exceeding its net assets, suggesting potential issues with asset quality [20][21]. Group 4: Market Reaction and Stock Performance - Despite the company's efforts to enhance investor confidence through share buybacks, the stock price has faced downward pressure, dropping over 60% from its peak [2][23]. - The company's financial metrics indicate that while revenue has surged, profitability remains weak, leading to skepticism in the market regarding its long-term viability [7][12]. Group 5: External Environment Impact - The company has cited adverse external conditions affecting its operations, particularly the impact of the COVID-19 pandemic on Lexmark's business, which has led to significant declines in sales and operational challenges [17][19]. - The overall financial health of the company has deteriorated, with rising debt levels and increasing financial pressure, prompting the decision to divest Lexmark [22][23].

Group 1: Company Performance and Financials - The company's revenue has significantly declined compared to 2018 and 2019, primarily due to the sale of Auno (China) Pharmaceutical Co., Ltd. in late 2019, which is no longer included in the consolidated financial statements [2] - In Q1 2025, the company's revenue decreased by 7.06% year-on-year, while net profit attributable to shareholders increased by 15.24% [6] - The company expects stable or slightly declining revenue for 2025, with continued growth in operating performance [6] Group 2: Product and Market Insights - Major products have been subjected to centralized procurement, with significant sales growth expected for the injection of multi-vitamins (over 40% in 2024) [3] - The company has a diverse product portfolio, including traditional Chinese medicine and various injectable products, with a focus on maintaining stable growth in existing products [6][10] - The company is primarily engaged in generic drug business, with plans to explore differentiated generics and high-barrier generics in the short term [10] Group 3: Corporate Structure and Shareholder Information - The company has undergone multiple acquisitions, with goodwill amounting to 369 million yuan as of the end of 2024, with no impairment risks identified [5] - Major shareholders include Shen Zhenyu and others, holding over 20% of total shares, with Shen Zhenyu's stake at approximately 10% as of Q1 2025 [13] - The company completed a share repurchase plan in March 2025, utilizing approximately 80 million yuan to buy back 32.31 million shares, representing 1.42% of the total share capital [11]

Core Viewpoint - Longbai Group, a leading global titanium dioxide and titanium products company, is facing increased pressure following the succession of the second generation of leadership, with significant cash dividends and share buybacks raising market skepticism about its financial health [1][3]. Financial Performance - Longbai Group announced a share buyback plan with a total expenditure of up to 1.086 billion yuan, alongside a cash dividend distribution of 1.186 billion yuan, resulting in a combined maximum expenditure of 2.186 billion yuan [2][5]. - As of the end of Q1 this year, the company reported monetary funds of 8.726 billion yuan against interest-bearing liabilities of approximately 26.3 billion yuan, indicating significant debt pressure [2][7]. - The company's net profit attributable to shareholders has been declining for three consecutive years, with Q1 2024 showing a further decrease [2][12]. Share Buyback and Dividend Strategy - The share buyback plan involves repurchasing shares at a maximum price of 24.82 yuan per share, which is approximately 50.15% higher than the market price of 16.53 yuan on the announcement date [3][4]. - The cash dividend for Q1 2024 is set at 5 yuan per 10 shares, totaling approximately 1.186 billion yuan, with a dividend payout ratio of 172.88% [4][5]. - For the entire year of 2024, the company plans to distribute cash dividends totaling 2.144 billion yuan, with a payout ratio nearing 98.89% of its annual profit [6]. Operational Challenges - Longbai Group's revenue and net profit have both declined in Q1 2024, with revenue at 7.06 billion yuan and net profit at 686 million yuan, representing year-on-year decreases of 3.21% and 27.86%, respectively [13]. - The company has faced operational pressures due to falling iron ore prices and underperformance in its new energy sector, contributing to the decline in net profit [2][12]. - The company has also recorded significant asset impairments, including a 342 million yuan impairment for goodwill related to previous acquisitions [12]. Company Background and Market Position - Longbai Group, originally known as Baili Union, has grown into a global leader in the titanium industry through a series of acquisitions and expansions, with a production capacity of 1.51 million tons per year for titanium dioxide and 80,000 tons for sponge titanium [10][12]. - The company holds over 1,270 patents in China, with a research and development investment of 1.175 billion yuan in 2024, maintaining a consistent R&D expenditure exceeding 1 billion yuan annually from 2021 to 2023 [11].

Core Viewpoint - InSai Group plans to acquire 80% of ZhiZhe TongHang for 641.6 million yuan, significantly increasing goodwill and enhancing its marketing capabilities [2][6]. Group 1: Acquisition Details - The acquisition will be executed through a combination of share issuance and cash payment, with a total valuation of ZhiZhe TongHang at 802 million yuan, reflecting a 513.62% increase in value [6]. - The transaction will result in an addition of 528 million yuan in goodwill, which will constitute 46.84% of InSai Group's total assets by the end of 2024 [6][9]. - InSai Group aims to raise up to 321 million yuan through a private placement to specific investors to support this acquisition [4]. Group 2: Financial Performance - In 2024, InSai Group is projected to report revenues of 883 million yuan, but will incur a net loss of 45.04 million yuan, marking its first loss since going public [8]. - The acquisition is expected to improve InSai Group's profitability, with projected revenues and net profits post-acquisition reaching 1.577 billion yuan and a net loss of 6.576 million yuan, respectively [9]. Group 3: Client Dependency and Risks - ZhiZhe TongHang has a high client concentration, with nearly 90% of its revenue coming from its top five clients, and over 52% from its largest client in 2024 [7][9]. - The company also faces significant accounts receivable, amounting to 172 million yuan, which represents 43.26% of its current assets [9].

Core Insights - Novaturas Group reported audited revenues of EUR 201 million for 2024, a 3.6% decline from 2023, with a total of 239,000 travelers served, down 8% from 259,000 in 2023 [1][17] - The company experienced a net loss of EUR 7.6 million for the year, primarily due to a one-off goodwill impairment of EUR 5.7 million [3][15] - Despite challenges in the first half of 2024, the company returned to profitability in the fourth quarter with an adjusted EBITDA of EUR 2.3 million [1][2] Financial Performance - Revenue for 2024 was EUR 200.9 million, compared to EUR 208.3 million in 2023 [15] - Gross profit decreased to EUR 20.7 million from EUR 26.2 million in 2023 [15] - The adjusted annual EBITDA was reported at EUR -449,000, while the net loss reached EUR -7.6 million [3][15] Operational Highlights - The first half of 2024 was marked by a challenging oversupplied market, leading to a negative EBITDA of EUR -1.6 million [1] - A stronger autumn and winter season improved results, with unaudited EBITDA at EUR -863,000 and a net loss of EUR -2.5 million [2] - The company successfully increased traveler numbers to popular destinations, with a 149% increase in trips to Spain and significant growth in long-haul travel sales [12][13] Strategic Developments - In early 2025, Novaturas entered a partnership with strategic investor Neset Kockar, acquiring a 23.2% stake, with plans for further acquisition to 33.19% [7][8] - The company plans to review its strategy and develop collaborations with the new shareholder's businesses to enhance offerings for Baltic travelers [9] - Novaturas is testing a hybrid travel packaging solution to provide a wider range of hotel options and pricing for clients [10] Market Trends - The company adjusted its travel offerings based on customer preferences, leading to higher operational efficiency [11] - Group travel segments, particularly sports and activity-based trips, gained popularity, with Turkey and Greece being favored destinations [13] - The share of last-minute bookings was successfully reduced, and the aircraft load factor increased to 98.9% in the fourth quarter [14]

近日，力盛体育发布定增预案（第四次修订稿），公司拟募资不超过3.3亿元，用来建设海南新能源汽 车体验中心国际赛车场项目。 作为中国首家上市的赛车运营企业，力盛体育曾头顶"中国赛车第一股"的光环，却在上市8年后陷入持 续亏损、频繁融资、并购暴雷的争议漩涡。2023年至2025年间，公司扣非净利润累计亏损超3亿元，定 增计划三度缩水，并购标的暴雷导致商誉减值近1.5亿元。这场资本盛宴背后，是战略失误还是其他原 因？ 2021-2024年，公司扣非净利润分别为-0.09亿元、-0.76亿元、-1.96亿元、-0.6亿元，累计亏损达3.4亿 元。力盛体育自2017年上市以来从未分红，未分配利润累计-1.59亿元。 力盛体育上市后三次募资（2017年IPO 1.69亿元、2021年定增3.9亿元、2023年拟募6亿元后缩至3.3亿 元），但募投项目屡现"烂尾"。 如 Xracing（汽车跨界赛）定增项目原定于 2022 年 12 月 31 日达到预 定可使用状态，因发行人拟将部分参赛用车进行电动化改装，达到预定可使用状态日期调整为 2024 年 12 月 31 日。 2021年，力盛体育以1.77亿元收购杭州峻石持有的 ...